qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

PCT/GB2015/052 – Rapid Screening and Evaluation of Diabetes and Prediabetes

Glycated Haemoglobin Mass Spectrometry. RK Iles, priority date 28th Aug 2014. Awarded United states of America Nov 2018. Currently filed and patent pending in: China (including Hong Kong), European Union, India, Japan and Brazil.

qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

National Filings/GB2014/050876- Prenatal Diagnosis

RK Iles, SA Butler, filed 20th March 2014, Priority date 22nd March 2013 published 25th September 2014. Awarded European Union and Japan Nov 20118. Currently filed and patent pending in: China (including Hong Kong), India and USA.

qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

PCT/GB2015/052,491 – Method for Detecting Abnormalities in Haemoglobin.

RK Iles, JK Iles, T Abban, SME Docherty, M Naase. Priority date 28th Aug 2014 Currently filed and patent pending in: China (including Hong Kong), European Union, India, Japan, UK and USA.

qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

PCT/GB2015/052,770- Method for providing a prognosis of pregnancy

RK Iles, SA Butler priority date 24th Sept 2014 Currently filed and patent pending in: China (including Hong Kong), Europe, India, Japan, UK and USA.

qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

GB Patent application20, 14, 6868- Mass Spectral Analysis of Urine and other Bodily Fluids for the Detection of Cancer Biomarkers.

RK Iles, SA Butler priority date 24th Sept 2014. Patent pending Great Britain

qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

National Filings/GB2014/051412 CGB2 AND CGB1 Genes; Diagnosis, Monitoring and Treatment of Cancer.

RK Iles, SA Butler Filed date 8th May 2014, Priority date 9th May 2013. Currently filed and patent pending in China, European Union and USA divisional.

qode-eliptic-slider

Our Portfolio

THE PATENT PORTFOLIO

PCT/GB2015/053,108 – Maternal metabolomics markers of foetal aneuploidy.

RK Iles, DP Trivedi priority date 20th Oct 2014. Currently filed as a GB application.

The Patents

The Group’s patent portfolio contains eight technologies, and combinations of technologies, at various stages of patent protection. Primary intellectual property priority is dated back to March 2013 and all patents have now reached the PCT (Patent Cooperation Treaty) or International Stage of patent filing. The treaty covers intellectual property protection in almost all global states (currently 149 nations) the first two of which are now, published. The same two patents are now in the national phase awaiting approval in each nation state where filed.

All patents are registered to, and owned by MAP IP Holding Ltd part of the MAP Sciences Group.

The method and approach of MALDI ToF MS analysis on urine, culture fluid and blood are protected by these individual patents or combined IP, within these patents and owned by MAP IP Holding Ltd. Intellectual property and knowhow are granted, through an exclusive license, to MAP Technologies LLC for development and commercial exploitation for up to 25 years.